轻度哮喘中按症状自我调整吸入激素与β2激动剂的模式:PRACTICAL试验预设分析
本研究为PRACTICAL随机对照试验的预设分析,纳入110名佩戴电子监测器的轻度哮喘患者,比较按需布地奈德-福莫特罗与维持布地奈德加按需特布他林两种方案下吸入激素(ICS)和β2激动剂的使用模式。结果显示按需组无ICS使用天数更多、每日布地奈德剂量更低,但β2激动剂等效剂量更高且过度使用天数更多。结论提示在轻度哮喘中,随β2激动剂使用而自我调整ICS的时机比ICS总剂量更重要。
要点
- 按需布地奈德-福莫特罗组无ICS使用天数中位数156天,显著多于维持组的22天。
- 按需组每日布地奈德剂量中位数164 μg,低于维持组的328 μg。
- 按需组β2激动剂等效剂量更高,过度使用天数(>8或>16喷)为33天 vs 维持组10天。
核心结论
- 在轻度哮喘中,当按需β2激动剂使用更频繁时,自我调整ICS的时机比ICS总剂量对减少重度急性发作风险更重要。
研究设计与样本
- PRACTICAL随机对照试验的预设分析,110名参与者佩戴电子监测器记录每次吸入的时间与日期,随访52周。
- 参与者1:1随机接受按需布地奈德-福莫特罗(200/6 μg,每次1吸)或维持布地奈德(200 μg,每日2次)加按需特布他林(250 μg,每次2吸)。
主要发现
- 按需布地奈德-福莫特罗组无ICS使用总天数中位数156天,维持布地奈德组为22天。
- 按需组每日布地奈德剂量中位数164 μg,维持组为328 μg。
- 按需组布地奈德≥4吸的天数中位数4天,维持组为1天。
- 按需组β2激动剂总体每日喷数中位数0.8喷,维持组为0.3喷。
- 按需组哮喘恶化时过度使用天数(>8或>16喷)总计33天,维持组为10天。
关键数值与推荐
- 一吸布地奈德-福莫特罗被认为与两吸特布他林等效支气管扩张剂量。
- 过度使用天数定义为布地奈德-福莫特罗或特布他林每日喷数>8或>16喷。
临床怎么用
- 轻度哮喘采用按需布地奈德-福莫特罗时,应关注ICS与β2激动剂同步使用的时机而非单纯累积ICS剂量。
- 电子监测可揭示患者实际用药模式,有助于识别β2激动剂过度使用并指导自我管理。
局限性
- 仅110名参与者佩戴电子监测器,样本量有限。
- 分析为预设亚组,结果需在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In mild asthma, as-needed budesonide-formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β2-agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β2-agonist use in PRACTICAL, a randomised controlled trial. METHODS: Participants were randomised 1:1 to as-needed budesonide-formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β2-agonist use. One actuation of budesonide-formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline. RESULTS: Participants randomised to as-needed budesonide-formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156 versus 22 days, respectively), lower median daily budesonide dose (164 versus 328 μg, respectively) and a greater median number of days of ≥4 budesonide actuations (4 versus 1 days, respectively). Participants randomised to as-needed budesonide-formoterol took higher equivalent doses of β2-agonist both overall (median number of actuations 0.8 versus 0.3 per day, respectively) and in response to worsening asthma (total number of "overuse days" of >8 or >16 actuations of budesonide-formoterol or terbutaline 33 versus 10 days, respectively). CONCLUSIONS: The timing of ICS dose when self-titrated to β2-agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β2-agonist.
引用
- Baggott C, Hardy J, Sparks J, et al. Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial. Eur Respir J. 2020. PMID: 32444401. doi:10.1183/13993003.00170-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。